Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma

Navarria, Pierina; Reggiori, G.; Pessina, Federico; Ascolese, A.M.; Tomatis, S.; Mancosu, P.; Lobefalo, F.; Clerici, Elena; Lopci, Egesta; Bizzi, Alberto; Grimaldi, Marco; Chiti, Arturo; Simonelli, Matteo; Santoro, Armando; Bello, Lorenzo; Scorsetti, Marta

doi:10.1016/j.radonc.2014.09.004

Cited by 45 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At present, delayed radiation-induced toxicity is underestimated because of the limited life expectancy and symptoms induced by disease progression, but its consideration is becoming increasingly essential. The current target volume concepts are not only prone to missing or underdosage of an essential proportion of the disease [2], but are also associated with unnecessary dose exposure of non-target normal tissues [3].…”

mentioning

confidence: 99%

Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma

et al. 2016

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Analogs of the somatostatin receptor subtype 2 (SSTR2), 68 Ga-DOTA-D-Tyr3-octreotate ( 68 Ga-DOTATATE) or 68 Ga-DOTA-D-Phe1-Tyr3-octreotide ( 68 Ga-DOTATOC), are used for improved target volume delineation for meningiomas [43] and glomus tumours [44]. In both entities, PET indispensably improves target volume delineation (especially following surgery), helps to reduce interobserver variability, and significantly alters the assessment of tumor extent compared to MRI alone.…”

Section: Somatostatin Receptor (Sstr) Analogsmentioning

confidence: 99%

“…In initial studies comparing MET or 68 Ga-DOTA-DPhe1-Tyr-octreotide ( 68 Ga-DOTATOC) PET/CT and PET/MRI performed on the same day, no significant artifacts and very good accordance of tumor-to-reference tissue ratios have been observed, indicating that anatomical and molecular imaging in patients with brain tumors is feasible with diagnostic imaging quality using simultaneous hybrid PET/MR image acquisition [65]. With advancing scanner technology, 68 Ga-DOTATOC-PET/ MRI now provides flawless image quality and presents an ideal combination of high sensitivity/specificity of tumor detection (PET) with the best possible morphological visualization of meningiomas (MRI) [66].…”

Section: Pet/mri For Target Volume Definition In Radiation Oncologymentioning

confidence: 99%

“…With advancing scanner technology, 68 Ga-DOTATOC-PET/ MRI now provides flawless image quality and presents an ideal combination of high sensitivity/specificity of tumor detection (PET) with the best possible morphological visualization of meningiomas (MRI) [66]. Indeed, clinical superiority of simultaneous PET/MR compared to separate MR and PET/CT has been prominently demonstrated in a case report describing target volume delineation for radiotherapy treatment planning in a patient with meningioma [67].…”

Section: Pet/mri For Target Volume Definition In Radiation Oncologymentioning

confidence: 99%

See 1 more Smart Citation

PET/MRI and brain tumors: focus on radiation oncology treatment planning

Oehlke

Grosu

2016

Clin Transl Imaging

View full text Add to dashboard Cite

In brain tumors, imaging by magnetic resonance imaging (MRI) can very accurately visualize anatomy and morphology of healthy and malignant tissue, but neither contrast-enhancing areas in T1-weighted sequences, nor hyperintensities in T2/FLAIR sequences are specific for tumor tissue, especially when considering the manifold alterations resulting from previous treatment. Imaging the biology of tumor tissue by positron emission tomography (PET), therefore, is a highly interesting approach to improve the detection of macroscopic tumor which is the prerequisite for high-precision radiotherapy treatment planning. This review will focus on the benefits of amino acid tracers (L-[methyl-11 C]methionine (MET) and O-(2-[ 18 F]fluoroethyl)-L-tyrosine (FET)) in neurooncology and their implementation in radiation oncology. Furthermore, a brief overview of the current impact of 2-deoxy-2-(18F)fluoro-D-glucose (FDG), nucleic acid analogs, hypoxia tracers, and Somatostatin receptor (SSTR) analogs on radiotherapy planning in brain tumors is provided. Among advances in multiparametric MRI, Diffusionweighted imaging (DWI) has attracted particular attention since it can predict prognosis, as well as indicate response to treatment and has already been introduced into target volume definition for radiotherapy of various cancers (e.g., prostate and rectal cancer). Additionally, advances in MR spectroscopy (MRS) are mentioned. Finally, these findings will be discussed concerning their influence on current aspects of integrated PET/MR hybrid imaging.

show abstract

“…C-MET PET was also found to provide supplementary information to MRI data, whereby BTV defined with 11 C-MET PET included all localizations of recurrences in a series of 52 glioblastomas (65). Thus, these pretreatment 11 C-MET PET volumes appear to identify areas at highest risk of recurrence for patients with glioblastomas since inadequate PET-gross-tumor-volume coverage was associated with increased risk of noncentral failures (66).…”

mentioning

confidence: 99%

PET Imaging in Glioblastoma: Use in Clinical Practice

Verger¹,

Langen²

2017

Glioblastoma

View full text Add to dashboard Cite

Positron emission tomography (PET) is a nuclear medicine imaging method with increasing relevance for the diagnosis, prognostication, and monitoring of glioblastomas. PET provides additional insight beyond magnetic resonance imaging (MRI) into the biology of gliomas, which can be used for noninvasive grading, differential diagnosis, delineation of tumor extent, planning of surgery, and radiotherapy and post-treatment monitoring. In clinical practice, two classes of radiotracers have been used predominantly for imaging purposes, namely glucose metabolism tracers and amino acid transport tracers. Both classes of tracers can provide information on grading and prognosis of gliomas, but amino acid tracers, which exhibit lower uptake in normal brain tissue, are better suited for delineation of tumor extent, treatment planning, or follow-up than 18 F-2-fluoro-2-deoxy-D-glucose ( 18 F-FDG). Owing to the progress in PET imaging using radiolabeled amino acids in recent years, the Response Assessment in Neuro-Oncology (RANO) working group, an international effort to develop new standardized response criteria for clinical trials in brain tumors, has recently recommended amino acid PET as an additional tool in the diagnostic assessment of brain tumors. PET Imaging in Glioblastomas 156These developments as well as multimodality imaging should improve the diagnostic assessment of these tumors.

show abstract

Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma

Cited by 45 publications

References 21 publications

Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma

Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma

PET/MRI and brain tumors: focus on radiation oncology treatment planning

PET Imaging in Glioblastoma: Use in Clinical Practice

Contact Info

Product

Resources

About